Clinical Trials Directory

Trials / Terminated

TerminatedNCT02112318

CArdioversion of Short Duration Atrial Fibrillation

Study of ECG-derived Atrial Fibrillatory Rate for Prediction of the Outcome of Cardioversion of Short Duration Atrial Fibrillation

Status
Terminated
Phase
Study type
Observational
Enrollment
32 (actual)
Sponsor
Region Skane · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is aimed at testing the hypothesis whether atrial fibrillary rate (AFR), as a measure of atrial electrical remodeling assessed from surface ECG, is predictive of sinus rhythm maintenance after electrical cardioversion. Earlier studies performed in a retrospective fashion suggested that high AFR exceeding 350-360 fibrillations per minute is an independent predictor of AF relapse after cardioversion, particularly in patients with duration of AF episode not exceeding 30 days, however this hypothesis has not been tested in a prospective study. CASAF is an observational study that will enroll patients with short duration (\< 30 days) AF admitted for electrical cardioversion. Admission ECG will be extracted in a digital format and processed off-line for estimation of AFR. AF relapse will be assessed during 6-weeks long follow-up period during which ECG control will be scheduled at week 1 and 6.

Conditions

Timeline

Start date
2013-01-01
Primary completion
2018-03-01
Completion
2021-03-01
First posted
2014-04-11
Last updated
2023-10-10

Locations

3 sites across 2 countries: Canada, Sweden

Source: ClinicalTrials.gov record NCT02112318. Inclusion in this directory is not an endorsement.